Login | Register

Addition of Everolimus to Exemestane Provides Sustained Edge in Women with Advanced Breast Cancer

SAN ANTONIO - The progression-free survival (PFS) benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, investigators announced at the San Antonio Breast Cancer Symposium (SABCS)...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *